VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
A phase 3 trial of Vusolimogene oderparepvec, Nivolumab, Relatlimab + nivolumab and Pembrolizumab in Advanced melanoma, run by Replimune, Inc., now recruiting.
Overview
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] is a phase 3 interventional study registered as NCT06264180 by Replimune, Inc., with 400 participants planned, started 2024-07-11 and due to reach its primary completion in 2030-09-30. Interventions recorded: Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy. Conditions recorded: Advanced Melanoma.
Linked to the drug Vusolimogene oderparepvec because the registry names it among its interventions and Advanced melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialIntratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Shares Vusolimogene oderparepvec, Pembrolizumab and the tag pipeline.
- TrialStudy to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab and the tag pipeline.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Nivolumab, Pembrolizumab and the tag pipeline.
- TrialStudy to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Shares Replimune and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares Nivolumab, Pembrolizumab and the tag pipeline.
- TrialMirdametinib in Patients With Advanced NF1-mutant Melanoma
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Advanced melanoma (unresectable stage III and stage IV) and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Shares Nivolumab, Pembrolizumab and the tag pipeline.